Chantal elects new board member.
The announcement was made by Chantal Burnison, chairman and chief executive officer.
This is the first in a series of steps that the company is taking to strengthen both its board and management, said Ms. Burnison. "Dr. Estrin's extensive experience, both domestically and internationally, and superb qualifications will be particularly valuable as the Company expands the marketing and distribution of its Ethocyn-based cosmetic products into the global marketplace," she said. Dr. Estrin has already been working with and will continue to serve as a consultant to the company, specifically with respect to the company's product launched into the Pacific Rim and other worldwide markets.
Dr. Estrin assists pharmaceutical, cosmetic and other companies in executing international marketing and distribution programs, including structuring and negotiating licensing and distribution arrangements, and in complying with FDA and other government regulatory requirements, including regulatory submissions. In addition, he serves as a consultant to government agencies, medical conference planning organizations and an international marketing management company. Dr. Estrin conceived, developed and edited several internationally recognized text books in the cosmetic industry, and is currently editing a new book, Cosmetic Regulation in a Competitive Environment.
Dr. Estrin brings to Chantal Pharmaceutical extensive expertise in the cosmetic industry, having held several management positions, including Senior Vice President-Science, at The Cosmetic, Toiletry and Fragrance Association from 1968 through 1985. While at CTFA, he created and edited the Cosmetic Ingredient Dictionary, which is recognized by the Food and Drug Administration and internationally as the official compendium for ingredient labeling.
Dr. Estrin left CFTA in 1985 to assume the position of Vice President - Science and Technology at the Health Industry Manufacturers Association, where he developed a number of international and domestic programs relating to the medical device industry.
Dr. Estrin also has served as a consultant to the National Cancer Institute, a research assistant at Florida State University in Tallahassee, Fla., and as a chemist at Clairol Research Laboratories in Stamford, Conn.
He received his doctorate in Physical-Organic Chemistry from Florida State University and is Regulatory Affairs Certified (RAC) by the Regulatory Affairs Professional Society. He serves on the board of The National Museum for Health & Medicine Foundation, The Institute for Advancement of Medical Communication and Discovery Pharmaceuticals, Inc., a company he co-founded in 1990. Dr. Estrin is a member of the Editorial Advisory Boards of the Medical Device Approval Letter and The Validation Consultant.
Chantal Pharmaceutical Corporation has executive offices, telemarketing and warehouse facilities in Los Angeles, with a laboratory in Kaiserslautern, Germany. In addition to marketing the Chantal Ethocyn Skin Care Line, the company is engaged in the research and development of androgen mediated disorders such as acne, hirsutism, male pattern baldness, benign prostate hypertrophy and the treatment of certain cancers.
CONTACT: Martin E. Janis & Company, Inc.
Bev Jedynak, 312/943-1100
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 6, 1996|
|Previous Article:||A New Writing Program For A New Generation Of Students Released By Prentice Hall School Division.|
|Next Article:||Triden Telecom Inc. Hires new COO, Signs Letter of Intent, Increases Revenues by $1.5 Million.|